IBI305 vs. Compounded Avastin – A Biosimilar Breakthrough for Safer and More Cost-Effective Retinal Therapies
DOI:
https://doi.org/10.63501/w2czew54Keywords:
Retinal diseases, Compounded bevacizumab, Intravitreal injections , Ophthalmic safety, Endophthalmitis prevention, IBI305 biosimilarAbstract
Retinal diseases, such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), demand accessible and safe therapies. Off-label use of bevacizumab (Avastin®) in ophthalmology raises safety concerns due to compounding practices, including risks of endophthalmitis and dose inconsistencies. The FDA/EMA-approved biosimilar IBI305 addresses these limitations with a single-use vial formulation, eliminating contamination risks and ensuring manufacturing compliance. Clinical studies confirm its pharmacokinetic equivalence to reference bevacizumab, with cost advantages enhancing its suitability for retinal disease management. Transitioning to IBI305 can improve safety, efficacy, and cost-efficiency, establishing it as a preferred therapeutic option.
References
[1]. Centers for Disease Control and Prevention (CDC), Multistate outbreak of postprocedural fungal endophthalmitis associated with a single compounding pharmacy—United States, March–April 2012, MMWR Morb Mortal Wkly Rep. (2012) 61, no. 17, 310–311. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6117a5.htm
[2]. Yannuzzi, N. A., Klufas, M. A., Quach, L., Beatty, L. M., Kaminsky, S. M., Crystal, R. G., D’Amico, D. J., & Kiss, S. (2015). Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmology, 133(1), 32–39. https://doi.org/10.1001/jamaophthalmol.2014.3591
[3]. U.S. Food and Drug Administration (FDA), Inspection of injectable products for visible particulates, FDA Guidance Document. (2021). Available at: https://www.fda.gov/media/154868/download
[4]. American Academy of Ophthalmology (AAO), The use of biosimilars in ophthalmic practice, AAO Clinical Statement. (2022). Available at: https://www.aao.org/education/clinical-statement/use-of-biosimilars-in-ophthalmic-practice
[5]. Zhang H., Zhu X., Wei H., Li C., Chen H., Li X., Wu M., Liu J., Chen G., Zhou H., Zheng S., Ding Y., A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects, Int J Clin Pharmacol Ther. (2019) 57, no. 3, 167–174. Available at: https://www.dustri.com/nc/article-response-page.html?artId=18045&doi=
Downloads
Published
Issue
Section
License
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, provided appropriate credit is given to the author(s) and the source. To view a copy of this license, visit: https://creativecommons.org/licenses/by/4.0